Growth in Vericel’s autologous cell therapy products reported

Date: September 14, 2017

Vericel’s commercial product line consists of MACI (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adults; Carticel (expanded autologous chondrocytes for the repair of articular cartilage injuries in patients with inadequate responses to prior arthroscopic or other surgical procedures) and Epicel (sheets of a patient’s own keratinocytes grown to replace skin lost following full thickness burns to at least 30% body surface area).

Q2 highlights reported include:

  • 28% growth in total MACI and Carticel net product revenues compared to the same period in 2016
  • 51% gross margins vs 43% in the same period in 2016
  • More than 350 surgeons trained on MACI surgical procedures to date
  • Distribution agreement with Orsini Healthcare for MACI
  • Standalone patient case management service launched as part of MACI patient support service
  • Data from over 950 severe burn patients treated with Epicel reported at the American Burn Association annual meeting demonstrating a probable survival benefit
  • Licensing of the company’s product portfolio to Innovative Cellular Therapeutics for distribution in China, South Korea and Singapore.

https://www.equities.com/news/vericel-vcel-revenue-growth-fueled-by-three-cellular-therapies

Back to News Overview
back to top